CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEX
Authors:
Open Access
- 11 July 2016
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (34) , 55328-55342
Abstract
CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEX CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEXKeywords
This publication has 46 references indexed in Scilit:
- Development of DNA aptamers using Cell-SELEXNature Protocols, 2010
- Aptamers Generated from Cell-SELEX for Molecular Medicine: A Chemical Biology ApproachAccounts of Chemical Research, 2009
- Targeted proteomic strategy for clinical biomarker discoveryMolecular Oncology, 2008
- CD109 expression in basal‐like breast carcinomaPathology International, 2008
- Cell-Specific Aptamer Probes for Membrane Protein Elucidation in Cancer CellsJournal of Proteome Research, 2008
- Protein biomarker discovery and validation: the long and uncertain path to clinical utilityNature Biotechnology, 2006
- Aptamers evolved from live cells as effective molecular probes for cancer studyProceedings of the National Academy of Sciences, 2006
- Cell surface antigen CD109 is a novel member of the α2 macroglobulin/C3, C4, C5 family of thioester-containing proteinsBlood, 2002
- In vitro selection of RNA molecules that bind specific ligandsNature, 1990
- Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA PolymeraseScience, 1990